接种SARS-CoV-2疫苗后的凝血病:唯一的解决方案可能会导致另一个问题

Q4 Medicine

Iranian Journal of Blood and Cancer Pub Date : 2022-12-01 DOI:10.58209/ijbc.14.4.125

Saeed Hassani, Meshkat Mesh Poortavakol, M. Sayyadi

{"title":"接种SARS-CoV-2疫苗后的凝血病:唯一的解决方案可能会导致另一个问题","authors":"Saeed Hassani, Meshkat Mesh Poortavakol, M. Sayyadi","doi":"10.58209/ijbc.14.4.125","DOIUrl":null,"url":null,"abstract":"The common reported adverse impacts of COVID-19 vaccination include the injection site's local reaction followed by various non-specific flu-like symptoms. Nevertheless, uncommon cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported. This literature review was performed using PubMed and Google Scholar databases using appropriate keywords and their combinations: SARS-CoV-2, adenovirus, spike protein, thrombosis, thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia (VITT), NF-kappaB, adenoviral vector, platelet factor 4 (PF4), COVID-19 Vaccine, AstraZeneca COVID vaccine, ChAdOx1 nCoV-19 COVID vaccine, AZD1222 COVID vaccine, coagulopathy. The s and titles of each article were assessed by authors for screening and inclusion English reports about post-vaccine CVST and VITT in humans were also collected. Some SARS-CoV-2 vaccines based on viral vector, mRNA, or inactivated SARS-CoV-2 virus have been accepted and are being pragmatic global. Nevertheless, the recent augmented statistics of normally very infrequent types of thrombosis associated with thrombocytopenia have been stated, predominantly in the context of the adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. The numerical prevalence of these side effects seems to associate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the meticulous molecular mechanisms are still not clear. The present review summarizes the latest data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis demonstrating that coagulopathies, including thromboses, thrombocytopenia, and other associated side effects, are correlated to an interaction of the two components in the COVID-19 vaccine.Copyright © 2022, Iranian Pediatric Hematology and Oncology Society. All rights reserved.","PeriodicalId":14581,"journal":{"name":"Iranian Journal of Blood and Cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem\",\"authors\":\"Saeed Hassani, Meshkat Mesh Poortavakol, M. Sayyadi\",\"doi\":\"10.58209/ijbc.14.4.125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The common reported adverse impacts of COVID-19 vaccination include the injection site's local reaction followed by various non-specific flu-like symptoms. Nevertheless, uncommon cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported. This literature review was performed using PubMed and Google Scholar databases using appropriate keywords and their combinations: SARS-CoV-2, adenovirus, spike protein, thrombosis, thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia (VITT), NF-kappaB, adenoviral vector, platelet factor 4 (PF4), COVID-19 Vaccine, AstraZeneca COVID vaccine, ChAdOx1 nCoV-19 COVID vaccine, AZD1222 COVID vaccine, coagulopathy. The s and titles of each article were assessed by authors for screening and inclusion English reports about post-vaccine CVST and VITT in humans were also collected. Some SARS-CoV-2 vaccines based on viral vector, mRNA, or inactivated SARS-CoV-2 virus have been accepted and are being pragmatic global. Nevertheless, the recent augmented statistics of normally very infrequent types of thrombosis associated with thrombocytopenia have been stated, predominantly in the context of the adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. The numerical prevalence of these side effects seems to associate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the meticulous molecular mechanisms are still not clear. The present review summarizes the latest data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis demonstrating that coagulopathies, including thromboses, thrombocytopenia, and other associated side effects, are correlated to an interaction of the two components in the COVID-19 vaccine.Copyright © 2022, Iranian Pediatric Hematology and Oncology Society. All rights reserved.\",\"PeriodicalId\":14581,\"journal\":{\"name\":\"Iranian Journal of Blood and Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Blood and Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.58209/ijbc.14.4.125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Blood and Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58209/ijbc.14.4.125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

常见的COVID-19疫苗接种不良反应包括注射部位的局部反应，随后出现各种非特异性流感样症状。然而，罕见的疫苗诱导的免疫性血栓性血小板减少症(VITT)和脑静脉窦血栓形成(CVST)在病毒载体疫苗(ChAdOx1 nCoV-19疫苗，Ad26)后。COV2疫苗)已被报道。使用PubMed和谷歌Scholar数据库进行文献综述，使用合适的关键词及其组合:SARS-CoV-2、腺病毒、刺突蛋白、血栓形成、血小板减少症、疫苗诱导的免疫性血小板减少症(VITT)、NF-kappaB、腺病毒载体、血小板因子4 (PF4)、COVID-19疫苗、阿斯利康COVID疫苗、ChAdOx1 nCoV-19 COVID疫苗、AZD1222 COVID疫苗、凝血功能障碍。作者对每篇文章的标题和标题进行了筛选和纳入，并收集了关于疫苗后人类CVST和VITT的英文报告。一些基于病毒载体、mRNA或灭活SARS-CoV-2病毒的SARS-CoV-2疫苗已被接受，并在全球范围内是实用的。然而，最近增加了与血小板减少症相关的通常非常罕见的血栓类型的统计数据，主要是在Astra Zeneca的腺病毒载体疫苗ChAdOx1 nCoV-19的背景下。这些副作用的数量流行率似乎与这种特殊的疫苗类型有关，即基于腺病毒载体的疫苗，但其细致的分子机制仍然不清楚。本综述将分子和细胞机制的最新数据和假设总结为一个综合假设，表明凝血功能障碍，包括血栓形成、血小板减少和其他相关副作用，与COVID-19疫苗中这两种成分的相互作用有关。版权所有©2022，伊朗儿童血液学和肿瘤学会。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem

The common reported adverse impacts of COVID-19 vaccination include the injection site's local reaction followed by various non-specific flu-like symptoms. Nevertheless, uncommon cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported. This literature review was performed using PubMed and Google Scholar databases using appropriate keywords and their combinations: SARS-CoV-2, adenovirus, spike protein, thrombosis, thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia (VITT), NF-kappaB, adenoviral vector, platelet factor 4 (PF4), COVID-19 Vaccine, AstraZeneca COVID vaccine, ChAdOx1 nCoV-19 COVID vaccine, AZD1222 COVID vaccine, coagulopathy. The s and titles of each article were assessed by authors for screening and inclusion English reports about post-vaccine CVST and VITT in humans were also collected. Some SARS-CoV-2 vaccines based on viral vector, mRNA, or inactivated SARS-CoV-2 virus have been accepted and are being pragmatic global. Nevertheless, the recent augmented statistics of normally very infrequent types of thrombosis associated with thrombocytopenia have been stated, predominantly in the context of the adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. The numerical prevalence of these side effects seems to associate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the meticulous molecular mechanisms are still not clear. The present review summarizes the latest data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis demonstrating that coagulopathies, including thromboses, thrombocytopenia, and other associated side effects, are correlated to an interaction of the two components in the COVID-19 vaccine.Copyright © 2022, Iranian Pediatric Hematology and Oncology Society. All rights reserved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Iranian Journal of Blood and Cancer Medicine-Oncology

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： IJBC tries to provide a new opportunity for advancing the field of Hematology and Oncology in Iran and make a bridge between Iranian researchers and fellow scientists globally. This journal is published in print and online and includes high quality manuscripts including basic and clinical investigations of blood disorders and malignant diseases namely: diagnosis, treatment, epidemiology, etiology, biology and molecular aspects as well as clinical genetics of these diseases, as they affect children, adolescents and adults. “IJBC” also includes the studies on transfusion medicine, hematopoietic stem cell transplantation, immunology, genetics and gene-therapy and accepts original papers, systematic reviews, case reports, brief reports and letters to the editor in all aspects of blood transfusion, blood donors recruitment, screening techniques, modern approaches to transfusion, whole blood and blood components applications.